Kindred Biosciences Announces Acquisition of Kansas Manufacturing Plant and Execution of Commercial Manufacturing Agreement for Zimeta

/in , , /by

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Monday, June 26, 2017 San Francisco, CA (June 26, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has acquired a manufacturing facility in […]

Read more →

Kindred Biosciences Added to the Russell 2000 Index

/in , , /by

San Francisco, June 15, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will join the US small-cap Russell 2000® Index, effective after the US market closes on June 23, according to a preliminary list of additions and the market capitalization […]

Read more →

Kindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary Internal Medicine Conference

/in , , /by

San Francisco, CA (May 30, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be presenting data from six studies at the 2017 American College of Veterinary Internal Medicine (ACVIM) conference in National Harbor, MD, held June 8-10, 2017.  The Company […]

Read more →

Kindred Biosciences to Present at 7th Annual LD Micro Invitational

/in , , /by

San Francisco, CA (May 24, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and COO, will be presenting and hosting one-on-one investor meetings at the 7th Annual LD Micro Invitational in Los Angeles, CA on Tuesday, June 6, 2017 at […]

Read more →

Kindred Biosciences Announces First Quarter 2017 Financial Results

/in , , /by

San Francisco, CA (May 3, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2017 and provided updates on its programs. “The first quarter of 2017 has been extremely successful for KindredBio. We continue to […]

Read more →